The gamma isoform of protein kinase C ( @entity25963 ) is an injury-activated intracellular modulator that boosts neuronal activity in algesic and neuroregenerative signalling pathways. @entity4162 (ALCAR), a physiological compound with role in bioenergetic functions, shows an antihyperalgesic effect and at the same time can exert neuroregenerative and neuroprotective effects. Aimed to explore the link between @entity158 and neuroregeneration, the effect of ALCAR treatment (100 mg kg(-1) i.p. twice daily for 15 days) on @entity25963 and mitogen-activated protein kinases (MAPKs) expression has been evaluated in @entity8638 ( @entity8638 ) @entity35 . The sciatic nerve and the lumbar tract of the spinal cord were processed to evaluate the levels of the phosphorylated form of @entity25963 , @entity2508 , @entity70244 , @entity12220 and c-Jun; furthermore, the mRNA expression of the early genes c-Jun and @entity5019 has been investigated. Fifteen days after injury, the analysis in the sciatic nerves highlighted a bilateral increase of the activated forms of @entity25963 , @entity2508 and @entity70244 , whereas c-Jun showed an increase only ipsilaterally. ALCAR completely prevented @entity1931 and provoked in the nerve a c-Jun increment only. In the lumbar tract of the spinal cord, higher levels of activated @entity25963 , @entity2508 , @entity12220 , @entity70244 and c-Jun proteins were detected in the ipsilateral side in respect of sham. ALCAR was able to stimulate this expression profile. At the transcriptional level c-Jun mRNA was increased in the ipsilateral side of spinal cord of @entity8638 saline-treated @entity35 , whereas @entity5019 mRNA was unchanged. ALCAR had a stimulatory effect on both these early genes. These findings may represent a different approach in the study of the complex balance between @entity158 and neuroregeneration and could constitute the basis for developing new disease modifying agents in the treatment of @entity9 .

The neuropathy-protective agent @entity4162 activates protein kinase C-gamma and MAPKs in a XXXX model of @entity9 .

@entity1931 :: ('MESH:D006930', 'Disease') :: ['mechanical hyperalgesia'] @entity2508 :: ('50689;116590', 'Gene') :: ['ERK 1,2'] @entity25963 :: ('24681(Tax:10116)', 'Gene') :: ['PKCgamma'] @entity4162 :: ('MESH:D000108', 'Chemical') :: ['Acetyl-L-carnitine'] @entity5019 :: ('314322(Tax:10116)', 'Gene') :: ['c-Fos'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity12220 :: ('81649(Tax:10116)', 'Gene') :: ['p38', 'p-38'] @entity8638 :: ('MESH:D020208', 'Disease') :: ['chronic constriction injury', 'CCI'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain'] @entity70244 :: ('29339;116554', 'Gene') :: ['SAP/JNK']
@entity35 :: (10116,Species) :: ['rat']
